[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-359686-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-359686-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","rna-m6a-modification-is-a-driver-and-therapeutic-target-in-gastric-cancer","RNA m6A modification is a driver and therapeutic target in gastric cancer","","N6-methyladenosine (m6A) is the most abundant eukaryotic RNA modification and a key regulator of RNA stability, expression, and translation. Dysregulated m6A regulators are detected in human gastric cancer tissues, influenced by Helicobacter pylori and transcription factors, and abnormal expression correlates with poor prognosis. Dynamic m6A regulation by methyltransferases, demethylases, and m6A-binding proteins shapes tumorigenesis, metastasis, stemness, immune evasion, and resistance to chemotherapy, radiotherapy, and immunotherapy. Aberrant m6A factor expression in blood supports biomarker potential, and targeted therapies against m6A regulators are promising for precision oncology.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/rna-m6a-modification-is-a-driver-and-therapeutic-target-in-gastric-cancer/359686/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/rna-m6a-modification-is-a-driver-and-therapeutic-target-in-gastric-cancer/359686.png","ImageObject",300,407,{"name":42,"@type":43},"Alex Sinclair","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",14,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What roles does m6A play in eukaryotic RNAs and gastric cancer?","Question",{"text":63,"@type":64},"m6A regulates RNA stability, expression, and translation. In gastric cancer, m6A modifications and their regulators affect tumor initiation, progression, immune evasion, and therapy resistance.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which proteins form the m6A “writers” complex?",{"text":68,"@type":64},"The core writer complex includes METTL3, METTL14, and WTAP, with auxiliary components such as KIAA1429 (VIRMA), RBM15/15B, and ZC3H13.",{"name":70,"@type":61,"acceptedAnswer":71},"How can m6A regulators be used clinically?",{"text":72,"@type":64},"Aberrant m6A regulatory factor expression in blood samples can serve as novel biomarkers. Therapies targeting m6A regulators are presented as promising precision treatment approaches.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},359686,1790210854,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},1099523882182,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Cell Biol Toxicol (2026) 42:53  \n[https://doi.org/10.1007/s10565-026-10141-y](https://doi.org/10.1007/s10565-026-10141-y)  \nRNA m6A modification is a driver and therapeutic target in gastric cancer  \nQingjuan Chen · Hongzhao Lu · Dezhi Li · Tao Liu  \nReceived: 15 October 2025 / Accepted: 4 January 2026  \n© The Author(s) 2026  \nAbstract N6-methyladenosine (m6A), the most abundant modification in eukaryotic RNAs, plays a critical role in regulating RNA stability, expression, and translation. Key m6A regulators are up- or down-regulated in human gastric cancer tissues, by Helicobacter pylori and transcription factors, and the aberrant expression is associated with poor patient prognosis. Dynamic m6A modification, orchestrated by methyltransferases, demethylases, and m6A-binding proteins, profoundly impacts gastric cancer tumorigenesis, metastasis, cancer cell stemness, immune evasion, and resistance to chemotherapy, radiotherapy, and immunotherapy. While aberrant m6A modifications and the expression levels  \nQingjuan Chen and Hongzhao Lu contributed equally to this work.  \nQ. Chen (*)  \nDepartment of Oncology, 3201 Hospital, Hanzhong, China  \ne-mail: [dr.qingjuan.chen@outlook.com](dr.qingjuan.chen@outlook.com)  \nH. Lu  \nCollege of Biological Science and Engineering, Shaanxi University of Technology, Hanzhong 723000, China  \nD. Li  \nDepartment of Oncology, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu 322000, China  \nT. Liu  \nUniversity of New South Wales, New South Wales, Sydney, NSW 2052, Australia  \nof its regulatory factors in blood samples are novel biomarkers in gastric cancer patients, therapies targeting m6A regulators have emerged as promising approaches for treating the disease. In summary, m6ARNA methylation represents a pivotal epitranscriptomic mechanism with significant implications for gastric cancer biology and precision oncology.  \nKeywords M6A methylation · M6A regulators · Gastric cancer · Tumorigenesis · Drug resistance · Cancer therapy  \nIntroduction  \nGastric cancer remains a significant global health burden, ranking as the fifth most commonly diagnosed malignancy and the third leading cause of cancerrelated mortality worldwide, with over one million new cases annually (Sung et al. 2021) . The prognosis for advanced gastric cancer remains poor, with a fiveyear survival rate below 30% in most regions (Rawla and Barsouk 2019) . The high mortality rate is largely attributable to late-stage diagnosis, rapid disease progression, and therapeutic resistance, underscoring the critical need for deeper mechanistic insights and precision therapies.  \nEpitranscriptomic regulations have emerged as essential modulators of tumour biology, complementing genomic and transcriptomic landscapes in shaping cancer progression. Among the diverse RNA  \nmodifications, N6-methyladenosine (m6A) represents the most prevalent modification in eukaryotic messenger RNA (mRNA) and non-coding RNAs, influencing RNA splicing, nuclear export, stability, decay and translation into proteins (Zaccara et al. 2019) . m6A modification is dynamically installed, removed, and interpreted by specific regulatory proteins known as “writers”(methyltransferases),“erasers”(demethylases), and “readers”(m6A-binding proteins), forming a reversible and finely tuned layer of gene expression control.  \nRecent studies have implicated dysregulation of m6A modification in various cancers, including gastric cancer, where m6A regulators modulate critical pathways involved in tumor initiation, progression, immune evasion, and therapy resistance (Denget al. 2023 ; Lan et al. 2021) . RNA m6A methylation affects key oncogenes and tumour suppressors by regulating RNA splicing, stability and translation, influencing gastric cancer cell proliferation, survival, migration, invasion, metastasis and immune responses (Deng et al. 2023 ; Lan et al. 2021), highlighting its potential as a diagnostic, prognostic, and therapeutic target.  \nThis review comp","cbCaidq0kfV0AZqp","https://ap.wps.com/l/cbCaidq0kfV0AZqp","pdf",3054648,21,"English","# Introduction\n# Brief overview of RNA m6A methylation and demethylation\n## m6A writers","[{\"question\":\"What roles does m6A play in eukaryotic RNAs and gastric cancer?\",\"answer\":\"m6A regulates RNA stability, expression, and translation. In gastric cancer, m6A modifications and their regulators affect tumor initiation, progression, immune evasion, and therapy resistance.\"},{\"question\":\"Which proteins form the m6A “writers” complex?\",\"answer\":\"The core writer complex includes METTL3, METTL14, and WTAP, with auxiliary components such as KIAA1429 (VIRMA), RBM15/15B, and ZC3H13.\"},{\"question\":\"How can m6A regulators be used clinically?\",\"answer\":\"Aberrant m6A regulatory factor expression in blood samples can serve as novel biomarkers. Therapies targeting m6A regulators are presented as promising precision treatment approaches.\"}]","RNA m6A modification is a driver and therapeutic target in gastric cancer | PDF",1790137541,53,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b34e8facb98a5d88c59836cf63698d98.webp",983,1324,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e5249d28bf66fbfc3dbd3270a4ce9c4e.webp",982,1322,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a061234f9c4e710398717224423c3274.webp",981,1321,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ad1512cce5eac91b4d8dd8c0e4e8b5f3.webp",980,1319]